Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Akorn Inc’s Hi-Tech Pharmacal infringes Allergan glaucoma drug patents

Written by: | no-reply@reuters.com | Dated: Tuesday, August 4th, 2015

Akorn Inc’s Hi-Tech Pharmacal Co, Inc infringed three Allergan Inc patents on its Lumigan topical glaucoma treatment, a U.S. appeals court ruled on Tuesday.

The U.S. Court of Appeals for the Federal Circuit also said five of Allergan’s Lumigan patents were valid. The case stems from lawsuits Allergan filed in 2011 against Hi-Tech, Novartis AG, and Lupin over proposed generic versions of Lumigan.

 

 

(Reporting by Andrew Chung; Editing by Meredith Mazzilli)


Source: Reuters

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom